NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SI
Post# of 137
(Total Views: 155)
Posted On: 06/21/2023 4:54:33 PM
NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 16/825,371 titled “Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis and Imaging of Diseases and Disorders.” According to the announcement, the new patent claims cover the company’s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue. “Our SPU-21 liposomal homing peptides, licensed from the University of Maryland, Baltimore, are able to identify markers of arthritic inflammation in joints and have potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis,” said Eric Weisblum, chief executive officer of Silo Pharma. “The expanded claims in this new patent grant reinforce protection for our ongoing development of SPU-21 guided delivery of targeted psilocybin as a therapeutic agent for rheumatoid arthritis (‘RA’), our initial indication.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 16/825,371 titled “Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis and Imaging of Diseases and Disorders.” According to the announcement, the new patent claims cover the company’s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue. “Our SPU-21 liposomal homing peptides, licensed from the University of Maryland, Baltimore, are able to identify markers of arthritic inflammation in joints and have potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis,” said Eric Weisblum, chief executive officer of Silo Pharma. “The expanded claims in this new patent grant reinforce protection for our ongoing development of SPU-21 guided delivery of targeted psilocybin as a therapeutic agent for rheumatoid arthritis (‘RA’), our initial indication.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)